Literature DB >> 25274791

A review of osteocyte function and the emerging importance of sclerostin.

Jocelyn T Compton1, Francis Y Lee1.   

Abstract

➤ Osteocytes, derived from osteoblasts, reside within bone and communicate extensively with other bone cell populations to regulate bone metabolism. The mature osteocyte expresses the protein sclerostin, a negative regulator of bone mass.➤ In normal physiologic states, the protein sclerostin acts on osteoblasts at the surface of bone and is differentially expressed in response to mechanical loading, inflammatory molecules such as prostaglandin E2, and hormones such as parathyroid hormone and estrogen.➤ Pathologically, sclerostin dysregulation has been observed in osteoporosis-related fractures, failure of implant osseous integration, metastatic bone disease, and select genetic diseases of bone mass.➤ An antibody that targets sclerostin, decreasing endogenous levels of sclerostin while increasing bone mineral density, is currently in phase-III clinical trials.➤ The osteocyte has emerged as a versatile, indispensable bone cell. Its location within bone, extensive dendritic network, and close communication with systemic circulation and other bone cells produce many opportunities to treat a variety of orthopaedic conditions.
Copyright © 2014 by The Journal of Bone and Joint Surgery, Incorporated.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25274791      PMCID: PMC4179450          DOI: 10.2106/JBJS.M.01096

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  121 in total

1.  Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats.

Authors:  Michelle M McDonald; Alyson Morse; Kathy Mikulec; Lauren Peacock; Nicole Yu; Paul A Baldock; Oliver Birke; Min Liu; Hua Zhu Ke; David G Little
Journal:  J Orthop Res       Date:  2012-03-27       Impact factor: 3.494

Review 2.  Regulation of bone remodeling by the central and peripheral nervous system.

Authors:  Florent Elefteriou
Journal:  Arch Biochem Biophys       Date:  2008-03-23       Impact factor: 4.013

3.  Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis.

Authors:  B Y Chan; E S Fuller; A K Russell; S M Smith; M M Smith; M T Jackson; M A Cake; R A Read; J F Bateman; P N Sambrook; C B Little
Journal:  Osteoarthritis Cartilage       Date:  2011-05-12       Impact factor: 6.576

4.  Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones.

Authors:  Michael S Ominsky; Chaoyang Li; Xiaodong Li; Hong L Tan; Edward Lee; Mauricio Barrero; Franklin J Asuncion; Denise Dwyer; Chun-Ya Han; Fay Vlasseros; Rana Samadfam; Jacquelin Jolette; Susan Y Smith; Marina Stolina; David L Lacey; William S Simonet; Chris Paszty; Gang Li; Hua Z Ke
Journal:  J Bone Miner Res       Date:  2011-05       Impact factor: 6.741

5.  Osteocytes use estrogen receptor alpha to respond to strain but their ERalpha content is regulated by estrogen.

Authors:  Gul Zaman; Helen L Jessop; Mariusz Muzylak; Roberto L De Souza; Andrew A Pitsillides; Joanna S Price; Lance L Lanyon
Journal:  J Bone Miner Res       Date:  2006-08       Impact factor: 6.741

6.  Novel SOST gene mutation in a sclerosteosis patient and her parents.

Authors:  Sanjay Kumar Bhadada; Ashu Rastogi; Ellen Steenackers; Eveline Boudin; Ashutosh Arya; Vandana Dhiman; Anil Bhansali; Wim Van Hul
Journal:  Bone       Date:  2012-10-16       Impact factor: 4.398

7.  Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.

Authors:  Teresita Bellido; A Afshan Ali; Lilian I Plotkin; Qiang Fu; Igor Gubrij; Paula K Roberson; Robert S Weinstein; Charles A O'Brien; Stavros C Manolagas; Robert L Jilka
Journal:  J Biol Chem       Date:  2003-10-01       Impact factor: 5.157

8.  Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover.

Authors:  Maria P Yavropoulou; Antoon H van Lierop; Neveen A T Hamdy; Rene Rizzoli; Socrates E Papapoulos
Journal:  Bone       Date:  2012-05-02       Impact factor: 4.398

Review 9.  Sclerostin: current knowledge and future perspectives.

Authors:  M J C Moester; S E Papapoulos; C W G M Löwik; R L van Bezooijen
Journal:  Calcif Tissue Int       Date:  2010-05-15       Impact factor: 4.333

10.  Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin.

Authors:  Daniel Mendoza-Villanueva; Leo Zeef; Paul Shore
Journal:  Breast Cancer Res       Date:  2011-10-27       Impact factor: 6.466

View more
  46 in total

Review 1.  The past 10 years-new hormones, new functions, new endocrine organs.

Authors:  Roger Bouillon; Daniel J Drucker; Ele Ferrannini; Steven Grinspoon; Clifford J Rosen; Paul Zimmet
Journal:  Nat Rev Endocrinol       Date:  2015-09-01       Impact factor: 43.330

Review 2.  Relaxin and insulin-like peptide 3 in the musculoskeletal system: from bench to bedside.

Authors:  Alberto Ferlin; Luca De Toni; Marco Sandri; Carlo Foresta
Journal:  Br J Pharmacol       Date:  2016-05-05       Impact factor: 8.739

3.  T-Type voltage-sensitive calcium channels mediate mechanically-induced intracellular calcium oscillations in osteocytes by regulating endoplasmic reticulum calcium dynamics.

Authors:  Genevieve N Brown; Pui L Leong; X Edward Guo
Journal:  Bone       Date:  2016-04-21       Impact factor: 4.398

4.  Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.

Authors:  Changjun Li; Weishan Wang; Liang Xie; Xianghang Luo; Xu Cao; Mei Wan
Journal:  Ann N Y Acad Sci       Date:  2015-04-02       Impact factor: 5.691

Review 5.  Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast.

Authors:  Michaela R Reagan; Lucy Liaw; Clifford J Rosen; Irene M Ghobrial
Journal:  Bone       Date:  2015-02-26       Impact factor: 4.398

Review 6.  [Regulation of bone metabolism in osteoporosis : novel drugs for osteoporosis in development].

Authors:  F Jakob; F Genest; G Baron; U Stumpf; M Rudert; L Seefried
Journal:  Unfallchirurg       Date:  2015-11       Impact factor: 1.000

7.  Specification of Sprouty2 functions in osteogenesis in in vivo context.

Authors:  Barbora Vesela; Eva Svandova; Maria Hovorakova; Renata Peterkova; Adela Kratochvilova; Martina Pasovska; Alice Ramesova; Herve Lesot; Eva Matalova
Journal:  Organogenesis       Date:  2019-09-04       Impact factor: 2.500

8.  Osteocyte Death and Bone Overgrowth in Mice Lacking Fibroblast Growth Factor Receptors 1 and 2 in Mature Osteoblasts and Osteocytes.

Authors:  Jennifer McKenzie; Craig Smith; Kannan Karuppaiah; Joshua Langberg; Matthew J Silva; David M Ornitz
Journal:  J Bone Miner Res       Date:  2019-06-17       Impact factor: 6.741

9.  An Acid-Activatable Fluorescence Probe for Imaging Osteocytic Bone Resorption Activity in Deep Bone Cavities.

Authors:  Ryu Hashimoto; Masafumi Minoshima; Junichi Kikuta; Shinya Yari; Steven D Bull; Masaru Ishii; Kazuya Kikuchi
Journal:  Angew Chem Int Ed Engl       Date:  2020-09-08       Impact factor: 15.336

10.  Microtubules tune mechanotransduction through NOX2 and TRPV4 to decrease sclerostin abundance in osteocytes.

Authors:  James S Lyons; Humberto C Joca; Robert A Law; Katrina M Williams; Jaclyn P Kerr; Guoli Shi; Ramzi J Khairallah; Stuart S Martin; Konstantinos Konstantopoulos; Christopher W Ward; Joseph P Stains
Journal:  Sci Signal       Date:  2017-11-21       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.